MNKD

EX-99.1

2 mnkd-ex99_1.htm

EX-99.1

EX-99.1

MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update

• Q3 2026 total revenues of $101.9 million, +24% vs. Q3 2025

• Q3 2026 commercial product revenue of $45.0 million, +102% vs. Q3 2025

o Furoscix ReadyFlow™ was approved and shipments commenced mid-September

o Rapid adoption of Furoscix ReadyFlow, making up approximately 75% of the current weekly Furoscix shipments

o Afrezza® pediatric launch accounts for an approximately 80% increase in average monthly new-to-brand prescriptions in Q3 vs. Q2 2026

• Pipeline Advancements

o Reported positive Phase 1b INFLO-1 results, demonstrating tolerability of nintedanib DPI and clinical validation of Technosphere DPI technology in IPF; global Phase 2 trial underway

• Conference call and webcast today at 4:30 p.m. ET

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., November 5, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD)

a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reported financial results for the third quarter of 2026, and provided a business update.

“The third quarter marked an important transition for MannKind as we shifted from delivering on three major catalysts to executing against them,” said Michael Castagna, Chief Executive Officer of MannKind. “We are focused on scaling two commercial launches while supporting three programs in IPF. Furoscix ReadyFlow is off to an exceptionally strong start, and we believe Furoscix will generate more revenue in the fourth quarter than it did in the first half of 2026. ReadyFlow significantly expands the opportunity ahead and reinforces our conviction that Furoscix can be transformational for MannKind and the patients we serve.”

Business Update

Commercial Products

Furoscix

• Furoscix® generated $22.4 million in net revenue for the third quarter of 2026, with Furoscix ReadyFlow shipments commencing in mid-September

• Approximately 75% of Furoscix shipments transitioned to ReadyFlow by late October, demonstrating rapid adoption following launch

• Achieved record monthly prescribers and prescriptions in September, reflecting continued growth in Furoscix utilization

Afrezza

• Afrezza® generated $19.3 million in net sales for the third quarter of 2026

• Total prescriptions increased approximately 17% compared with Q2 2026, driven by strong early uptake following the pediatric launch

• All 60 priority pediatric institutions have prescribed Afrezza, with approximately 2,000 pediatric patients treated since launch

Development

Nintedanib DPI (MNKD-201)

• Positive Phase 1b INFLO-1 results demonstrated tolerability of nintedanib DPI, validating the Technosphere® DPI platform in IPF

• Advancing MNKD-201 into global Phase 2 trial

Ralinepag DPI (MNKD-1501)

• Formulation work completed; United Therapeutics plans to pursue clinical development

• Anticipate earning $15 million in milestone payments in 2027

Inhaled GLP-1 Program

• Entered into a licensing and collaboration agreement with Rose Pharma to develop an inhaled rapid-acting, short-duration GLP-1 for weight management

Corporate Update

• Cash, cash equivalents and investments as of September 30, 2026, totaled $96.6 million

• Closed $50 million private placement on July 24, 2026; proceeds funded the $45 million CVR payment triggered by the FDA approval of Furoscix ReadyFlow

Third Quarter 2026 Financial Results

Revenues

Three Months Ended September 30,

2026

2025

$ Change

% Change

Revenues

(Dollars in thousands)

Afrezza

19,349

18,493

856

5

%

Furoscix

22,376

—

22,376

N/A

V-Go

3,277

3,812

(535

)

(14

%)

Collaborations and services

19,405

26,506

(7,101

)

(27

%)

Royalties

37,463

33,319

4,144

12

%

Total revenues

$

101,870

$

82,130

$

19,740

24

%

Total revenues for the third quarter of 2026 increased compared to the same period in the prior year primarily due to the addition of Furoscix to our product portfolio following the October 2025 acquisition of scPharma, as well as an increase in revenue from royalties. The increase in royalties was due to UT’s increase in net revenue from sales of Tyvaso DPI. The increase in total revenue was partially offset by a decrease in revenue from collaborations and services which was primarily attributable to decreased product sold to UT. UT provides notice of their subsequent year purchase quantity on or prior to October 15th of each year and quarterly revenue fluctuations reflect delivery timing rather than changes in annual order volume.

Operating Expenses and Other Financial Highlights

 Cost of goods sold – commercial, excluding amortization of acquired intangible assets, was $11.2 million for the three months ended September 30, 2026, compared to $4.5 million for the same period in 2025.

 The increase is primarily attributable to the inclusion of Furoscix into o

EX-99.1

2 mnkd-ex99_1.htm

EX-99.1

EX-99.1

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

• Achieved three major catalysts to drive future growth:

o Launched the pediatric indication of Afrezza® following FDA approval

o FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKD

o Positive nintedanib DPI Phase 1b data in IPF patients validates continued Phase 2 advancement

• Encouraging early momentum in Afrezza pediatric launch

o 1 in 3 of the top 100 pediatric insulin writers have prescribed

• Q2 2026 total revenues of $109.4M, +43% vs. Q2 2025

• Conference call and webcast today at 4:30 p.m. ET

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., August 5, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD)

a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reported financial results for the second quarter of 2026, and provided a business update.

“This was a transformative period for MannKind, during which we delivered all three major catalysts we set out to achieve in 2026,” said Michael Castagna, Chief Executive Officer of MannKind. “The two recent FDA approvals are expected to fuel our near-term growth opportunities to help patients living with diabetes, heart failure and CKD. The positive Phase 1b INFLO-1 results for MNKD-201 reduces development risk and strengthens our confidence in the ability of our platform to help people living with IPF and other fibrotic diseases. Together, these milestones validate our diversification strategy and position MannKind for sustainable growth.”

Business Update and Upcoming Milestones

Commercial Products

• Revenue from marketed products (Afrezza, Furoscix®) grew 27% from Q1 2026 to Q2 2026

Furoscix

• Furoscix (furosemide injection) generated $22.2 million in net sales for Q2 2026

• Continued growth in Integrated Delivery Networks, increasing doses purchased by 36% over Q1 2026

• Record number of nephrology units dispensed, increasing by 67% over Q1 2026

• Received FDA approval of Furoscix ReadyFlow™ on July 23, 2026, the first and only autoinjector delivering IV-equivalent diuretic therapy for the treatment of edema in adults with heart failure (HF) or chronic kidney disease (CKD); expected to be commercially available in late August

Afrezza

• Afrezza (insulin human) Inhalation Powder generated $17.0 million in net sales for Q2 2026

• Received FDA approval of Afrezza on May 29, 2026 for use in children and adolescents ages 6 and older living with diabetes

• Awarded Breakthrough T1D grant supporting advancement of INHALE-1ST, a pediatric trial of Afrezza in youth with newly diagnosed type 1 diabetes

Development

Nintedanib DPI (MNKD-201)

• Topline data readout of U.S. Phase 1b INFLO-1 demonstrates safety and tolerability in IPF patients

• Site activation and enrollment underway in the global Phase 2 INFLO-2 study

Ralinepag DPI (MNKD-1501)

• On track for IND filing by year end

• Received a $5 million payment from United Therapeutics (UT) to support the rapid advancement of ralinepag DPI

Corporate Update

• Cash, cash equivalents and investments as of June 30, 2026, totaled $111 million

• Closed $50 million private placement on July 24, 2026; proceeds will fund the $45 million CVR payment triggered by the FDA approval of Furoscix ReadyFlow

Second Quarter 2026 Financial Results

Revenues

Three Months Ended June 30,

2026

2025

$ Change

% Change

Revenues

(Dollars in thousands)

Afrezza

17,021

18,329

(1,308

)

(7

%)

Furoscix

22,191

—

22,191

N/A

V-Go®

2,770

4,125

(1,355

)

(33

%)

Collaborations and services

35,022

22,845

12,177

53

%

Royalties

32,370

31,228

1,142

4

%

Total revenues

$

109,374

$

76,527

$

32,847

43

%

Total revenues for the second quarter of 2026 increased compared to the same period in the prior year due to the addition of Furoscix to our product portfolio through the October 7, 2025 acquisition of scPharma, as well as increases in collaborations and services revenue, and royalties. The increase in collaborations and services revenue was primarily attributable to increased product sold to UT and revenue earned related to the development of ralinepag DPI. The increase in royalties was due to UT’s increase in net revenue from sales of Tyvaso DPI.

Operating Expenses and Other Financial Highlights

 Cost of goods sold – commercial, excluding amortization of acquired intangible assets, was $14.4 million for the three months ended June 30, 2026, compared to $4.6 million for the same period in 2025.

 The increase is primarily attributable to the inclusion of Furoscix into our product portfolio following the acquisition of scPharma in October 2025. Gross margin percentage decreased in the current period due to the inclusion of Furoscix, which has a lower gross margin percentage than Afrezza.

 Research and develo

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.ce06d217.1784385676.ac418145

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.